论文部分内容阅读
近日,中国科学院北京基因组研究所慈维敏课题组、刘江课题组和北京大学第一医院周利群课题组合作,深入探讨了5m C(5-甲基胞嘧啶)和5hm C(5-羟甲基胞嘧啶)在透明肾细胞癌中的重编程变化模式和规律,发现5hm C是肾癌潜在的预后标志物,同时5hm C在肾癌发生过程中可能的驱动作用及其分子机制,寻找到一种潜在的肿瘤治疗新策略.该研究于2015年12月18日在线发表在Cell Research上[1].北京基因组研究所陈科、张靖和第一医院博士生郭中强为该论文的共同第一作者.
Recently, the Chinese Academy of Sciences Beijing Genomics Group Civitamin task force, Liujiang Task Force and Peking University First Hospital Zhou Liqun task force cooperation, in-depth discussion of 5m C (5-methylcytosine) and 5hm C Cytosine) in renal cell carcinoma of renal cell carcinoma in the process of reprogramming patterns and found that 5hm C is a potential prognostic marker of renal cell carcinoma, while 5hm C in the process of renal cell carcinoma may be the driving force and its molecular mechanisms to find A potential new strategy for oncology treatment.The study was published online at Cell Research on December 18, 2015. [1] Chen Ke, Zhang Jing from Beijing Genomics Institute and Guo Zhongqiang from Doctoral Candidate of First Hospital contributed to the common An author.